82 results about "Compound specific" patented technology

Families of compositions are provided as labels, referred to as eTag reporters for attaching to polymeric compounds and assaying based on release of the eTag reporters from the polymeric compound and separation and detection. For oligonucleotides, the eTag reporters are synthesized at the end of the oligonucleotide by using phosphite or phosphate chemistry, whereby mass-modifying regions, charge-modifying regions and detectable regions are added sequentially to produce the eTag labeled reporters. By using small building blocks and varying their combination large numbers of different eTag reporters can be readily produced attached to a binding compound specific for the target compound of interest for identification. Protocols are used that release the eTag reporter when the target compound is present in the sample.

The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed.

This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.

A DMS-IMS chemical sensing system employs two ion-separation technologies in tandem to extract signals of specific chemicals from the glut of signals present. The sensing system generally includes an atmospheric pressure ion generation system, a Differential Mobility (DMS) system, a time-of-flight IMS (TOF-IMS) system, and an ion detector system. The DMS extracts a narrow range of trace chemicals from an environmental sample for subsequent analysis, and a TOF-IMS then analyzes the resulting narrow range of isolated chemicals, allowing compound-specific detection thresholds at sub-ppb concentrations.

The invention discloses a method and a special quantum dot fluorescent immunoassay kit for detecting quinolone compounds. The quantum dot fluorescent immunoassay kit for detecting the quinolone compounds provided by the invention comprises specific antibodies, coating antigens and standard solution of the quinolone compounds, wherein the coating antigens are conjugates of hapten and carrier proteins of the quinolone compounds. Experiments prove that the kit of the invention has the characteristics of simple sample pretreatment process, simple and convenient operation, low cost, high specificity, high sensitivity, high accuracy, on-site monitoring, suitability for screening of a large number of samples, and the like.

Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.

This invention relates to one method to test pyrazine compound in alcohol in liquor taste study, which applies top fix phase micro extraction and gas phase spectrum and flame thermal ion test device and uses gas phase spectrum and flare thermal ion test device cross technique in liquor with strong abnormal property of compound with good linear relation for R2>0.99 and compound test limit less than 1 mu g / L; Repeating the test relative standard bias for less than 15 percent and recycle rate larger than 80 percent.

The invention belongs to the technical field of energy storage materials, relates to a nitrogen-doped carbon / nickel / nickel oxide nanocomposite preparation method, is used for supercapacitor electrodematerial preparation occasions, and solves the problem that a traditional technology has many preparation steps and costs long time and low compound specific capacitance is not conducive to material application. A crosslinked polyacrylamide of a 3D structure / nickel salt aerogel are used as a precursor and a self-template, through calcination treatment, in-situ nitrogen doping and catalytic graphitization of the carbon material are realized and a three-dimensional hierarchical porous structure is formed, nickel nanoparticles are uniformly distributed in a carbon matrix, a metal elementary substance surface layer is oxidized to nickel oxide, a ternary composite material is formed, the preparation technology is simple in steps, is energy-saving and environment-friendly, the principle is reliable, a product has the high specific surface area of the carbon material, high conductivity of metallic nickel, typical pseudocapacitance characteristics of nitrogen-doped carbon and nickel oxide, andthe composite material has excellent electrochemical performance, is environment-friendly in use, and thus has good economic benefits and broad market prospects.

Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.

This invention pertains to compounds which specifically inhibit the adenosine A3 receptor and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are versatile vehicles for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. Any kind of compound, but in particular drugs, such as interferons, viral reverse transcriptase inhibitors or core assembly inhibitors, and / or labels can be specifically targeted to the liver and so be enriched in the liver. This liver targeting can further be used for the targeted diagnosis, prevention and / or treatment of liver diseases or disorders, such as hepatitis, malaria, hepatocellular carcinoma (HCC), as well as for the prevention of HAV, HBV, HCV and / or HDV infection. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified preS-derived peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to a method for the combined treatment of a liver disease and the prevention of HAV, HBV, HCV and / or HDV infection. The present invention relates also to the use of the preS-derived peptides in gene therapy and the delivery of immunogenic epitopes for hepatocyte-mediated antigen presentation to activate liver-directed immunological responses.

The invention provides methods and compositions for identifying and counting lymphocytes in a biological sample, such as whole blood, by means of a probe comprising at least one binding compound specific for a T lymphocyte-specific marker, e.g. a CD2 or CD3, and at least one binding compound specific for CD45RA. Lymphocytes within the sample combine with such a probe to form a distinguishable subpopulation based on the amount of probe that specifically binds to their surfaces, thereby permitting such lymphocytes to be detected and enumerated on the basis of the intensity of the signal generated by the probe, and without the need of a separate physical measurement, such as light scatter. With additional probes specific for additional blood cell markers, percentages of lymphocytes, monocytes and granulocytes in a sample may be determined.

Mass spectrometer parameters used to tune a mass spectrometer for multiple reaction monitoring (MRM) are determined from a single injection of a sample. Two or more precursor ion scans and a plurality of product ion scans for each precursor ion scan are performed from the injection. Each precursor ion scan is produced with different mass spectrometer parameters that create a different level of ion current. The mass spectra of the precursor ion scans are analyzed to determine if saturation has occurred in any of the precursor ion scans. A precursor ion scan that produces the highest ion current with the least amount of saturation is selected. The mass spectrometer parameters used to tune the mass spectrometer for MRM are determined from (1) the mass spectrometer parameters of the selected precursor ion scan and (2) the mass spectrometer parameters of product ion scans from fragments of the selected precursor ion scan.

Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.

This invention pertains to compounds which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

The present invention relates to a method for real-time measurement of the secretion of at least one compound by at least one individual cell, comprising:the culturing, in a liquid medium, of at least one cell in a culture chamber, at least one wall of which comprises at least one sensitive area, a sensitive area comprising a plurality of ligands, attached to a solid support, each ligand being able to bind specifically to the compound, and an element for real-time transduction of a signal produced by the binding of the compound to one of the ligands;the identification, in a sensitive area, of at least one spot producing a signal;the real-time measurement of the signal produced by the spot identified, representing the amount of compound secreted by an individual cell.

The invention provides methods and compositions for detecting the presence of, or for measuring amounts of, molecular complexes, particularly complexes comprising two or more proteins, such as receptor complexes of cell surface membranes. In one aspect of the invention, reagent pairs are provided that comprise a cleaving probe that specifically binds to at least one component of a molecular complex and one or more signaling reagents that specifically bind to one or more components of the molecular complex, at least one of which is different from the component to which the cleaving probe is attached. Each signaling reagent comprises a binding compound specific for a component of the molecular complex and a signaling polynucleotide attached thereto by a cleavable linkage. When the reagent pairs are bound to the same molecular complex, the cleaving probe may be induced to generate a reactive species that is capable of cleaving cleavable linkages within an effective proximity, thereby releasing a signaling polynucleotide by which the molecular complex is detected.

The invention belongs to the field of microorganisms, and in particular provides a microbial composition for promoting tobacco growth. The microbial composition is formed by compounding specific Bacillus tequilensis, Enterobacter cloacae, Klebsiella variicola and Enterobacter xiangfangensis strains at a ratio. The microbial composition can effectively improve agronomic characters of tobacco, adjust the proportion of beneficial microorganisms in the soil, and increase the yield of tobacco and the proportion of superior tobacco.

The invention belongs to the energy storage material technical field, and relates to a graphene / nitrogen doped carbon / nickel / nickel oxide composite material preparation method; the method is applied to a super capacitor electrode material preparation occasion, and solves the problems that an existing process is complex in preparation steps, long in time consumption, low in compound specific capacitance, and hard in material applications. The method comprises the following steps: employing a reduction oxidation graphene / crosslinking polyacrylamide / nickel salt aerogel as a precursor; calcining same to realize carbon material in situ nitrogen doping, carbon hot reduction, and catalysis graphitization; and compositing same with the reduction oxidation graphene to form a 3D structure graphene / nitrogen doped carbon / nickel / nickel oxide quaternary nano composite material. The preparation process is simple, and reliable in principles; the composite material can serve as the super capacitor electrode material, is low in equivalent resistance, low in interface charge transfer resistance and Warburg impedance, high in product specific capacitance, excellent in electrochemistry performance, andhas excellent economic benefits and application prospects.

The present invention provides a pharmaceutical preparation comprising a compound which can be obtained by reacting a compound having a free amino group with a sugar having the reducing power. The preparation is capable of improving the in vivo durability of various compounds and releasing the compounds in response to changes in pH, and thus is useful for causing the compounds to act specifically on target parts.

The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and / or treatment of liver diseases or disorders.

The invention relates to the field of molecular biology and tumor pharmacology and discloses a marker related to auxiliary diagnosis of cancer cells or tumors. The marker is NATD or a combination of NATD and Slug. The invention provides a quick, simple and convenient detection method of the non-small cell lung cancer marker. The detection method can serve as an auxiliary means for early diagnosis of the non-small cell lung cancer or other urothelial tumors. In addition, NATD serving as an epigenetic inheritance modification enzyme can screen antibodies or small molecule compounds specific to protein to inhibit activity of the protein, so that the objective of treating the non-small cell lung cancer and other urothelial tumors is achieved.

The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.

The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and / or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens. The surrogate compounds may be prepared by covalently joining two or more polypeptide epitopes using one or more linkers, wherein at least one of the epitopes comprises a post-translational modification. In one aspect, the surrogate compounds of the invention comprise a C-terminal epitope and a glycated epitope of human CD59. The inventive methods allow quantification of the levels of glycated CD59 in the serum in human subjects, particularly those with diabetes or pre-diabetes. This technological platform of post-translationally modified protein surrogates can be applied to other diseases associated with post-translationally modified proteins (e.g., autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus). In another aspect, the invention provides antibodies that bind specifically to the compounds of the invention and methods for producing such antibodies.

Families of compositions are provided as labels, referred to as eTag reporters for attaching to polymeric compounds and assaying based on release of the eTag reporters from the polymeric compound and separation and detection. For oligonucleotides, the eTag reporters are synthesized at the end of the oligonucleotide by using phosphite or phosphate chemistry, whereby mass-modifying regions, charge-modifying regions and detectable regions are added sequentially to produce the eTag labeled reporters. By using small building blocks and varying their combination large numbers of different eTag reporters can be readily produced attached to a binding compound specific for the target compound of interest for identification. Protocols are used that release the eTag reporter when the target compound is present in the sample.